Csl

CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.

The designations would entitle CSL Behring to exclusively market recombinant factor VIIa fused with albumin in Europe for a period of 10 years if the product at the stage of license application fulfils the orphan drug requirements..

Source: http://www.science20.com/newswire/csl_behring_receives_eu_orphan_drug_designations_rviiafp_hemophilia_and_b_treatment-79541

Created by: popper | Created at: 08:05 PM
Ad Ranking: 2.2